Hybridize Therapeutics

[On Demand]
Hybridize Therapeutics (2019) is a biotech spin-off from the Nephrology department of the Leiden University Medical Center. Hybridize is based in Leiden which contains a rich ecosystem in both Nephrology & RNA-based therapeutics. Here, both the dialysis machine and the first antisense oligonucleotide were invented.

Hybridize combines these areas and therefore its mission is to help patients overcome untreated kidney diseases with high unmet need using RNA-based therapeutics. Our main program focuses on the BK-virus.

Next to this, we are extending our pipeline towards kidney monogenic diseases & anti-inflammation / fibrosis.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Antisense oligonucleotide targeting BK-virus
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Hybridize Therapeutics